- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON, Wis., Dec.

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, Wis.-- ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

Exact Sciences Corporation EXAS recently presented new data highlighting the clinical value of the Oncotype DX Breast Recurrence Score test at the 2021 San Antonio Breast Cancer Symposium (SABCS). The ...

REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...

Studies Presented at the 29th Annual San Antonio Breast Cancer Symposium Define Roles and Relationships of Genes Measured by Oncotype DX Recurrence Score Kaiser Permanente and the National Surgical ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial ...

REDWOOD CITY, Calif., Dec. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

At first glance, given that the two assays share only one overlapping gene, it would appear that the two assays have little in common in terms of genomic content. However, the priority gene lists are ...